መነሻ › አቶፒክ ደርማቲቲስ (ኤክዜማ) › Oregon
በOregon ለአቶፒክ ደርማቲቲስ (ኤክዜማ) የሚደረጉ ክሊኒካዊ ጥናቶች
ለአቶፒክ ደርማቲቲስ (ኤክዜማ) የሚደረጉ 6 ጥናቶች በOregon ባሉ ቦታዎች ተሳታፊዎችን እየፈለጉ ነው።
በOregon ውስጥ ያሉ ከተሞች
Official study text (English)
A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis
- Investigational Site, Portland
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ23 ሴፕቴ 2026 · NCT07003425A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
- Inmagene Site 3, Portland
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ ከ18 እስከ 74 · ሁሉም ጾታዎች · የተሻሻለው በ12 ኦገስ 2026 · NCT07037901A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis
- Oregon Health and Science University /ID# 266483, Portland
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ ከ2 እስከ 11 · ሁሉም ጾታዎች · የተሻሻለው በ6 ኦገስ 2026 · NCT06461897A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis
- Leo Pharma Investigational site, Portland
ተሳታዮችን በመፈለግ ላይደረጃ 3
6 Months – 11 Years · ሁሉም ጾታዎች · የተሻሻለው በ7 ጁላይ 2026 · NCT06311682A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab
- Oregon Health and Science University /ID# 263736, Portland
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ ከ18 እስከ 63 · ሁሉም ጾታዎች · የተሻሻለው በ6 ጁላይ 2026 · NCT06389136Real-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults
- Galderma Investigational Site 7073, Gresham
ተሳታዮችን በመፈለግ ላይየመመልከት ጥናት
እድሜ 12 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ13 ማርች 2026 · NCT06988605ከ ClinicalTrials.gov የተገኘ መረጃ፣ በ5 ኦክቶ 2026 የተሰብሰቡ። እያንዳንዱ ጥናት የራሱን ቅድመ ሁኔታ ይወስናል፤ የጥናት ቡድኑ ማን መሳተፍ እንደሚችል ይወስናል።